Supriya Lifescience Limited has informed the Exchange about Investor Presentation
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience filed its Q4 & FY25 investor presentation on May 27, 2025. For Q4 FY25, revenue grew 16% YoY to INR 1,841.1 Mn, EBITDA rose 22% to INR 675.8 Mn, and PAT jumped 38% to INR 503.8 Mn. For full-year FY25, revenue grew 22% YoY to INR 6,964.8 Mn, EBITDA surged 51% to INR 2,608.0 Mn, and PAT rose 58% to INR 1,879.6 Mn, with EPS at INR 23.35. EBITDA margin expanded 712 bps to 37.4% and PAT margin improved 610 bps to 27.0% for FY25, driven by 72% revenue from backward-integrated products. The company also announced a 10-year exclusive CMO contract with a leading European company, expected to generate peak revenue of INR 60 cr/year starting FY27, with two more similar opportunities in the pipeline.
Strong FY25 results with significant margin expansion and a multi-year CMO contract visibility could be positive for the stock. Investors should note that the new CMO revenue will only start flowing from FY27, so near-term impact is limited to the strong existing business performance.